4 completed, 2 terminated, 1 active not recruiting, 1 recruiting. 10 Phase 2, 4 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 10 | Completed 4, Terminated 2, Active not recruiting 1, Recruiting 1, Unknown 1, Withdrawn 1 |
| Phase 1 | 4 | Completed 3, Active not recruiting 1 |
Follow Relapsed Diffuse Large B-cell Lymphoma: new trials by email Literature Review of Relapsed Diffuse Large B-cell Lymphoma trials Research Report on Relapsed Diffuse Large B-cell Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Treatment of Relapsed or Refractory Diffuse Large B Cell Lymphoma With Ociperlimab (BGB-A1217) in Combination With Tislelizumab (BGB-A317) or Rituximab Ociperlimab, Tislelizumab, Rituximab - Relapsed Diffuse Large B-cell Lymphoma, Refractory Diffuse Large B-cell Lymphoma | Phase 1 / Phase 2 | Completed | BeiGene | 53 | 2022-04-25 | 2025-09-15 |
| Trial of Loncastuximab Tesirine in High Risk Diffuse Large B-cell Lymphoma Post Transplant loncastuximab tesirine - Relapsed Diffuse Large B-cell Lymphoma | Phase 2 | Withdrawn | Barbara Ann Karmanos Cancer Institute | 2022-04-08 | 2023-11-01 | |
| Copanlisib Plus Venetoclax in R/R DLBCL Copanlisib, Venetoclax - Diffuse Large B Cell Lymphoma, Relapsed Diffuse Large B-Cell Lymphoma | Phase 1 / Phase 2 | Active not recruiting | Dana-Farber Cancer Institute | 48 | 2021-09-08 | 2026-01-07 |
| Treatment of CD79B Mutant Relapsed/Refractory Diffuse Large B-Cell Lymphoma With Bruton Tyrosine Kinase Inhibitor Zanubrutinib Zanubrutinib - Relapsed Diffuse Large B-cell Lymphoma, Refractory Diffuse Large B-cell Lymphoma | Phase 2 | Completed | BeiGene | 65 | 2021-08-11 | 2026-03-25 |
| DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma DPX-Survivac, Pembrolizumab, CPA - Relapsed Diffuse Large B-cell Lymphoma, Refractory Diffuse Large B-cell Lymphoma | Phase 2 | Recruiting | ImmunoVaccine Technologies, Inc. (IMV Inc.) | 102 | 2021-06-18 | 2023-04-07 |
| Sintilimab Plus R-GemOx as Second-line Salvage Therapy in Patients With R/R DLBCL Sintilimab - Diffuse Large B Cell Lymphoma, Relapsed Diffuse Large B-Cell Lymphoma | Phase 2 | Unknown | Qian Wenbin | 51 | 2020-12-10 | 2020-12-09 |
| PK,PD,Safety and Tolerability of Multiple Dose Regimens of MT-3724 With Gemcitabine and Oxaliplatin for the Treatment of Patients With Relapsed/Refractory Diffuse Large B Cell Non-Hodgkin's Lymphoma MT-3724, Gemcitabine, Oxaliplatin - Non-hodgkin Lymphoma,B Cell, Refractory Diffuse Large B-Cell Lymphoma | Phase 2 | Terminated | Molecular Templates, Inc. | 8 | 2018-08-20 | 2022-08-16 |
| Atezolizumab, Rituximab, Gemcitabine and Oxaliplatin in Patients With Relapsed or Refractory DLBCL Not Suitable for High-dose Therapy Atezolizumab, Rituximab, Gemcitabine 1000 mg - Diffuse Large B Cell Lymphoma, Relapsed Diffuse Large B-Cell Lymphoma | Phase 2 | Terminated | University Hospital Southampton NHS Foundation Trust | 53 | 2018-05-09 | 2022-08-22 |
| Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Participants With Refractory Aggressive Non-Hodgkin Lymphoma Axicabtagene Ciloleucel, Fludarabine, Cyclophosphamide - Refractory Diffuse Large B Cell Lymphoma (DLBCL), Relapsed Diffuse Large B-Cell Lymphoma | Phase 1 / Phase 2 | Completed | Kite, A Gilead Company | 307 | 2015-04-21 | 2024-06-04 |
| Ibrutinib in Combination With Lenalidomide and Rituximab in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma Ibrutinib, Lenalidomide, Rituximab - Relapsed Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma | Phase 1 / Phase 2 | Completed | Pharmacyclics LLC. | 138 | 2014-03-13 | 2022-02-04 |
Lymphoma, Large B-Cell, Diffuse (10) · Lymphoma (1) · Neoplasms (1) · Recurrence (1)
Hemic and Lymphatic Diseases (10) · Immune System Diseases (10) · Immunoproliferative Disorders (10) · Lymphatic Diseases (10) · Lymphoma, B-Cell (10) · Lymphoma, Non-Hodgkin (10) · Lymphoproliferative Disorders (10) · Neoplasms by Histologic Type (10) · Lymphoma (9) · Neoplasms (9) · Disease Attributes (1) · Pathologic Processes (1) · Pathological Conditions, Signs and Symptoms (1)
Rituximab (4) · Gemcitabine (3) · Oxaliplatin (3) · Cyclophosphamide (2) · Bendamustine Hydrochloride (1) · Carboplatin (1) · Cisplatin (1) · Dexamethasone (1) · Doxorubicin (1) · Etoposide (1) · Ifosfamide (1) · Lenalidomide (1) · Levetiracetam (1) · Methylprednisolone (1) · Prednisone (1)
BeiGene (2) · Barbara Ann Karmanos Cancer Institute (1) · Dana-Farber Cancer Institute (1) · ImmunoVaccine Technologies, Inc. (IMV Inc.) (1) · Kite, A Gilead Company (1) · Molecular Templates, Inc. (1) · Pharmacyclics LLC. (1) · Qian Wenbin (1) · University Hospital Southampton NHS Foundation Trust (1)
United States (6) · China (3) · Canada (2) · France (2) · Germany (2) · United Kingdom (2) · Australia (1) · Belgium (1) · Hungary (1) · Israel (1) · Netherlands (1) · New Zealand (1) · Poland (1) · Romania (1) · Serbia (1)
Andy Davies (1) · Dipenkumar Modi, M.D. (1) · Jennifer Crombie, MD (1) · Jutta K. Neuenburg, MD, PhD (1)
PMID 29226797, PMID 30518502, PMID 31331917, PMID 33035333, PMID 33334730, PMID 34296427, PMID 34310745, PMID 34493319, PMID 34515338, PMID 36618900, PMID 36821768, PMID 38635762, PMID 39240498
2015 (1), 2016 (1)